Polson R J, Jawad A S, Bomford A, Berry H, Williams R
Liver Unit, King's College Hospital, Denmark Hill, London.
Q J Med. 1986 Dec;61(236):1153-8.
Desferrioxamine was used to treat six patients who had rheumatoid arthritis refractory to conventional treatment, on the basis that levels of intra-articular iron would be reduced and inflammation lessened. After a period of initial intensive treatment which was limited by side effects, five patients continued on once-weekly maintenance doses. Two patients had temporary improvement in their symptoms, but relapsed in spite of continuing treatment. The remaining three patients completed six months of treatment with no improvement in their rheumatoid disease. There were no significant changes in rheumatological parameters, immunological markers of disease activity nor radiological evidence of improvement. Treatment did lead to significant falls in haemoglobin concentration (p less than 0.01), mean corpuscular volume (p less than 0.05) and serum ferritin levels (p less than 0.02). Therefore, in spite of a reduction in iron available for haem synthesis and a fall in tissue storage iron the rheumatoid inflammatory process persisted.
去铁胺被用于治疗6名对传统治疗无效的类风湿性关节炎患者，基于这样的想法，即关节内铁水平会降低且炎症会减轻。在经历了一段因副作用而受限的初始强化治疗期后，5名患者继续接受每周一次的维持剂量治疗。2名患者症状暂时改善，但尽管持续治疗仍复发。其余3名患者完成了6个月的治疗，类风湿疾病并无改善。风湿病参数、疾病活动的免疫标志物均无显著变化，也没有影像学改善的证据。治疗确实导致血红蛋白浓度显著下降（p<0.01）、平均红细胞体积下降（p<0.05）和血清铁蛋白水平下降（p<0.02）。因此，尽管用于血红素合成的铁减少且组织储存铁下降，但类风湿性炎症过程仍持续存在。
